Is Vertex Stock Still a Good Buy?
Over the past ten years or so, Vertex Pharmaceuticals (NASDAQ:…
Buy
70
PDEX Quote, Financials, Valuation and Earnings
Last price:
$67.56
Seasonality move
:
2.43%
Day range:
$65.73 - $70.25
52-week range:
$16.84 - $70.26
Dividend yield:
0%
P/E ratio:
33.20x
P/S ratio:
3.71x
P/B ratio:
6.80x
Volume:
44.9K
Avg. volume:
43.9K
1-year change:
260.87%
Market cap:
$216.5M
Revenue:
$53.8M
EPS (TTM):
$2.00
Analysts' Opinion
-
Consensus RatingPro-Dex has received a consensus rating of Buy. The company's average rating is a Buy based on 1 Buy rating, 0 Hold ratings, and 0 Sell ratings.
-
Price Target DownsideAccording to analysts' consensus price target of $54.00, Pro-Dex has an estimated downside of -18.68% from its current price of $66.40.
-
Price Target UpsideAccording to analysts, the highest upside price target is $54.00 representing -100% upside increase from its current price of $66.40.
Fair Value
-
According to the consensus of 1 analyst, Pro-Dex has -18.68% downside to fair value with a price target of $54.00 per share.
PDEX vs. S&P 500
-
Over the past 5 trading days, Pro-Dex has overperformed the S&P 500 by 3.2% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Pro-Dex does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Pro-Dex has grown year-over-year revenues for 6 quarters straight. In the most recent quarter Pro-Dex reported revenues of $16.8M.
Earnings Growth
-
Pro-Dex has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Pro-Dex reported earnings per share of $0.61.
Enterprise value:
228.2M
EV / Invested capital:
--
Price / LTM sales:
3.71x
EV / EBIT:
24.30x
EV / Revenue:
3.74x
PEG ratio (5yr expected):
0.24x
EV / Free cash flow:
139.39x
Price / Operating cash flow:
138.18x
Enterprise value / EBITDA:
21.53x
Gross Profit (TTM):
$18.3M
Return On Assets:
12.54%
Net Income Margin (TTM):
11.06%
Return On Equity:
21.59%
Return On Invested Capital:
15.21%
Operating Margin:
16.03%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $44.2M | $48.2M | $61M | $12.6M | $16.8M | |
| Gross Profit | $11.9M | $13.6M | $18.3M | $2.8M | $5.1M | |
| Operating Income | $4.3M | $6.3M | $10.3M | $777K | $2.7M | |
| EBITDA | $9.6M | $5.6M | $10.6M | $1M | $3.1M | |
| Diluted EPS | $1.58 | $0.84 | $2.00 | $0.14 | $0.61 | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $22.7M | $26.1M | $31.4M | $36.6M | $44.3M | |
| Total Assets | $38.4M | $42.1M | $47.6M | $51.4M | $60.4M | |
| Current Liabilities | $4.9M | $6M | $11.7M | $10M | $17.1M | |
| Total Liabilities | $16.5M | $20.1M | $23.1M | $19.6M | $28.6M | |
| Total Equity | $21.8M | $22M | $24.5M | $31.8M | $31.8M | |
| Total Debt | $8.9M | $12.2M | $12.7M | $12.1M | $16.4M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$2.6M | $4.1M | $2.8M | $710K | -$4.2M | |
| Cash From Investing | -$403K | -$2.3M | -$1.2M | -$1.9M | -$542K | |
| Cash From Financing | -$1.9M | -$864K | -$2.9M | $558K | $1.7M | |
| Free Cash Flow | -$3.8M | $3M | $1.6M | $77K | -$4.7M | |
PDEX
Sector
Market Cap
$216.5M
$34.9M
Price % of 52-Week High
94.51%
44.35%
Dividend Yield
0%
0%
Shareholder Yield
3.88%
-0.82%
1-Year Price Total Return
260.87%
-38.5%
Beta (5-Year)
0.400
0.738
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$64.10
200-day SMA
Buy
Level
$37.47
Bollinger Bands (100)
Buy
Level
37.93 - 56.11
Chaikin Money Flow
Sell
Level
-5.6M
20-day SMA
Buy
Level
$59.82
Relative Strength Index (RSI14)
Buy
Level
63.40
ADX Line
Buy
Level
35.73
Williams %R
Neutral
Level
-24.3528
50-day SMA
Buy
Level
$48.96
MACD (12, 26)
Buy
Level
4.89
25-day Aroon Oscillator
Buy
Level
48
On Balance Volume
Neutral
Level
15.6M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.3222)
Buy
CA Score
(Annual)
Level (0.6701)
Sell
Beneish M-Score
(Annual)
Level (2.4147)
Buy
Momentum Score
Level (10)
Sell
Ohlson Score
Level (1.5094)
Buy
Piotroski F Score
(Annual)
Level (6)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (8)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Pro-Dex Inc is engaged in the design, development, and manufacture of autoclavable, battery-powered and electric, multi-function surgical drivers and shavers used in the orthopedic, thoracic, and craniomaxillofacial (CMF) markets. The company also designs and manufactures multi-axis motion control systems used in factory automation and scientific research markets. Majority of the company's revenue is derived from designing, developing, and manufacturing surgical devices for the medical device and dental industries.
Stock Forecast FAQ
In the current month, PDEX has received 1 Buy ratings 0 Hold ratings, and 0 Sell ratings. The PDEX average analyst price target in the past 3 months is $54.00.
-
Where Will Pro-Dex Stock Be In 1 Year?
According to analysts, the consensus estimate is that Pro-Dex share price will drop to $54.00 per share over the next 12 months.
-
What Do Analysts Say About Pro-Dex?
Analysts are divided on their view about Pro-Dex share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Pro-Dex is a Sell and believe this share price will rise from its current level to $54.00.
-
What Is Pro-Dex's Price Target?
The price target for Pro-Dex over the next 1-year time period is forecast to be $54.00 according to 1 Wall Street analyst, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is PDEX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Pro-Dex is a Buy. 1 of 1 analysts rates the stock a Buy at this time.
-
How Can I Buy Shares Of PDEX?
You can purchase shares of Pro-Dex via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Pro-Dex shares.
-
What Is The Pro-Dex Share Price Today?
Pro-Dex was last trading at $67.56 per share. This represents the most recent stock quote for Pro-Dex. Yesterday, Pro-Dex closed at $66.40 per share.
-
How To Buy Pro-Dex Stock Online?
In order to purchase Pro-Dex stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Okta Stock Finally Gaining Investor Confidence?
Given how digital transformation has proliferated, cyberattacks have also been…
Is The Trade Desk the Best Advertising Stock Now?
The worldly backdrop is now shrouded in heavy uncertainty and…
Stock Ideas
Buy
59
Is AAPL Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 35x
Buy
58
Is MSFT Stock a Buy?
Market Cap: $2.9T
P/E Ratio: 33x
Buy
55
Is NVDA Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 37x
Alerts
Buy
85
HIMS alert for Apr 30
Hims & Hers Health [HIMS] is down 6.59% over the past day.
Buy
54
EAT alert for Apr 30
Brinker International [EAT] is down 2.65% over the past day.
Sell
16
NSP alert for Apr 30
Insperity [NSP] is down 5.34% over the past day.
